| |
No fibrosis N (%)
|
Significant fibrosis N (%)
|
Crude
|
Adjusted
|
|---|
|
Baseline variable
| | |
OR (95% CI)
|
P
|
OR (95% CI)
|
P
|
|---|
|
Gender
|
|
Female
|
99 (53.2)
|
17 (23.0)
|
1
| |
1
| |
|
Male
|
87 (46.8)
|
57 (77.0)
|
3.8 (2.1–7.0)
|
<0.001
|
3.0 (1.5–5.9)
|
0.002
|
|
Age group (years)
|
|
18–25
|
41 (22.0)
|
12 (16.2)
|
1
| |
1
| |
|
26–35
|
92 (49.5)
|
23 (31.1)
|
0.9 (0.4–1.9)
|
0.695
|
1.5 (0.6–3.9)
|
0.406
|
|
36–45
|
30 (16.1)
|
22 (29.7)
|
2.5 (1.1–5.8)
|
0.033
|
4.4 (1.5–12.8)
|
0.006
|
|
> 45
|
23 (12.4)
|
17 (23.0)
|
2.5 (1.0–6.2)
|
0.043
|
3.6 (1.2–11.0)
|
0.022
|
|
Alcohol abuse
|
|
No
|
184 (98.9)
|
71 (95.9)
|
1
| | | |
|
Yes
|
2 (1.1)
|
3 (4.1)
|
3.9 (0.6–23.8)
|
0.142
| | |
|
HBeAg (n = 255)
|
|
Negative
|
174 (95.1)
|
60 (83.3)
|
1
| |
1
| |
|
Positive
|
9 (4.9)
|
12 (16.7)
|
3.9 (1.6–9.6)
|
0.004
|
2.7 (0.9–8.4)
|
0.087
|
|
HBV genotype (n = 68)
|
|
A
|
38 (82.6)
|
19 (86.4)
|
1
| | | |
|
D
|
8 (17.4)
|
3 (13.6)
|
0.8 (0.2–3.2)
|
0.695
| | |
|
HDV co-infection (n = 259)
|
|
No
|
180 (97.3)
|
72 (97.3)
|
1
| | | |
|
Yes
|
5 (2.7)
|
2 (2.7)
|
1.0 (0.2–5.3)
|
1.000
| | |
|
ALT (U/L)
|
|
≤ 40
|
166 (89.2)
|
56 (75.7)
|
1
| |
1
| |
|
> 40
|
20 (10.8)
|
18 (24.3)
|
2.7 (1.3–5.4)
|
0.006
|
1.8 (0.8–4.0)
|
0.162
|
|
HBV viral load (IU/ml) (n = 259)
|
|
< 2000
|
114 (61.6)
|
37 (50.0)
|
1
| |
1
| |
|
2000–19,999
|
47 (25.4)
|
9 (12.2)
|
0.6 (0.3–1.3)
|
0.198
|
0.7 (0.3–1.6)
|
0.350
|
|
≥ 20,000
|
24 (13.0)
|
28 (37.8)
|
3.6 (1.9–7.0)
|
<0.001
|
3.2 (1.4–7.4)
|
0.006
|
-
OR odds ratio, CI confidence interval, HBeAg hepatitis B e-antigen, HBV hepatitis B virus, HDV hepatitis D virus, ALT alanine aminotransferase
